Insilico Medicine has reached a striking milestone: its first profit arrived alongside $106.3 million in revenue during the first half of 2026. The company’s results show where that money came from, and the answer is clear—deal-making around drug discovery, not software sales.
Insilico posted a net profit of $35.54 million and an adjusted net profit of $51.23 million in its first interim report since listing on the Hong Kong Stock Exchange. The numbers give the company’s generative AI drug discovery strategy a financial result that is impossible to overlook.
Deals, Not Software, Drove the Revenue
Insilico reported $106.3 million in revenue for the first half of 2026, with nearly all of it coming from transactions connected to drug discovery and pipeline development. Revenue from that business reached $103.1 million, while software solutions revenue stood at $2.70 million.
That split puts the company’s business model in sharp focus. Insilico has software solutions, but the first-half results were powered by agreements tied to drug programs rather than sales of software or an approved product. The cash that arrived during the period produced the $106.3 million in reported revenue.
The company’s announced transaction value also climbed to approximately $7.3 billion in 2026. The figure reflects the scale of the partnerships surrounding its pipeline, although the largest deals are framed as “up to” amounts that represent ceilings if all milestones are hit.
That distinction matters. A deal headline can show the full possible value of a collaboration, while the revenue recorded in a period reflects the cash that arrived during that period. Insilico’s first-half results therefore connect its profit to payments already received, while the wider transaction total points to future milestones and obligations tied to the agreements.
Two Major Partnerships Expand the Pipeline
In June 2026, Insilico announced a $2.5 billion AI drug discovery collaboration with SK Biopharmaceuticals. The agreement became one of the company’s biggest announced transactions and added major weight to its 2026 dealmaking total.
In July 2026, Insilico announced a strategic collaboration with Takeda Pharmaceutical totaling approximately $600 million. That amount includes roughly $60 million in project initiation fees, near-term payments, and milestones, giving the partnership a clear mix of immediate and future financial components.
Together, these collaborations show how Insilico is converting AI-enabled discovery work into partnerships with pharmaceutical companies. The results do not show software revenue leading the business; they show dealmaking around drug discovery and pipeline development driving the period.
Clinical Progress Gives the Deals a Drug Pipeline Behind Them
Insilico’s most clinically advanced asset is rentosertib, also known as ISM001-055. The program has initiated a large-scale Phase III trial in China for idiopathic pulmonary fibrosis, placing it at the leading edge of the company’s clinical pipeline.
Rentosertib also gained regulatory progress in April 2026, when a nebulized inhalation formulation received IND clearance from China’s Center for Drug Evaluation. Insilico has pointed to rentosertib as proof that a generative AI-discovered target and molecule can reach patients.
That program gives the company’s financial story a clinical anchor. The revenue came from dealmaking, but the partnerships connect to a pipeline that includes a drug candidate in a large-scale Phase III trial and a formulation that received IND clearance in China.
Another program moved forward in 2026. The brain-penetrant NLRP3 inhibitor ISM8969/HT-001, co-developed with Hygtia Therapeutics, received US FDA IND approval in January 2026 and completed first-in-human dosing in a Phase I trial in June 2026.
These milestones place clinical development beside the company’s partnership activity. Rentosertib has reached Phase III in China for idiopathic pulmonary fibrosis, while ISM8969/HT-001 has entered human testing after US FDA IND approval.
A New Test for AI Drug Discovery
Insilico’s August 26, 2026 results capture a company moving from promise to measurable commercial output. Its first profit, $106.3 million in first-half revenue, and approximately $7.3 billion in announced 2026 transaction value all center on the same engine: drug discovery and pipeline development powered by AI.
The next question is how much of the “up to” deal value becomes revenue as milestones arrive. The answer will depend on payments, project progress, and clinical development, but the company already has a clear marker in rentosertib: an AI-discovered target and molecule advancing through clinical testing toward patients.
